Who is sponsoring NCT05436223?

NCT05436223 is sponsored by Hrain Biotechnology Co., Ltd..

What drugs are being tested in NCT05436223?

Interventions in NCT05436223: Human CD19Targeted T Cells Injection.

What condition does NCT05436223 study?

NCT05436223 studies B-cell Non-Hodgkin's Lymphoma.

Is NCT05436223 still recruiting?

NCT05436223 is currently recruiting now. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT05436223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting now Phase 2 Last updated 5 July 2022

What this trial tests

Phase 2 trial testing Human CD19Targeted T Cells Injection in B-cell Non-Hodgkin's Lymphoma in 100 participants. Currently enrolling.

Timeline

9 August 2021

Primary endpoint
9 August 2024

9 August 2026

Quick facts

Lead sponsor	Hrain Biotechnology Co., Ltd.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	9 August 2021
Primary completion	9 August 2024
Estimated completion	9 August 2026
Sites	1 location across China

Drugs / interventions tested

Human CD19Targeted T Cells Injection — full drug profile →

Conditions studied

B-cell Non-Hodgkin's Lymphoma — all drugs for B-cell Non-Hodgkin's Lymphoma →

Sponsor

Hrain Biotechnology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with B-cell Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for B-cell Non-Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT07081022 — JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting

Other Hrain Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT06045091 — To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL · EARLY_PHASE1 · recruiting
NCT05651191 — To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL · EARLY_PHASE1 · unknown
NCT05651178 — Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients · EARLY_PHASE1 · recruiting
NCT05594797 — Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM · Phase 2 · recruiting
NCT05223686 — To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05436223 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hrain Biotechnology Co., Ltd.
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05436223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing